Status:
UNKNOWN
Assessment of Patients With Hepatitis C Virus Related Liver Cirrhosis After Sustained Response to Direct Acting Anti Viral Drugs.
Lead Sponsor:
Assiut University
Conditions:
Hepatitis C
Liver Cirrhosis
Eligibility:
All Genders
18+ years
Brief Summary
Hepatitis C Virus (HCV) infection is a major global health challenge; it is estimated that more than 80 million people are chronically infected worldwide, with 3-4 million new infections and 350,000 d...
Detailed Description
In 2015, a national Egyptian health issue survey was conducted to describe the prevalence of hepatitis C virus infection. The prevalence of hepatitis C virus antibody was found to be 10.0% and that of...
Eligibility Criteria
Inclusion
- Age: ≥ 18 years.
- Disease status: patients with hepatitis C Virus related liver cirrhosis child A\& B (scores 5-9).
- Previous treatment: treatment naïve and treatment experienced.
- HCV RNA: Negative at any point between 12-24 weeks post treatment to confirm successful eradication of the virus.
- Negative HBsAg and HIV antibody.
- Normal kidney function test
Exclusion
- Child C liver cirrhosis (Child score ≥ 10).
- HCV coinfection with HBV or HIV.
- Patients with high risk of infection (I.V drug users, patients with blood disease requiring blood transfusion).
Key Trial Info
Start Date :
December 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03241823
Start Date
December 1 2017
End Date
March 1 2019
Last Update
August 8 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assuit Unit of Treatment of Viral Hepatitis.
Asyut, Egypt, 71111